Stock Ratings / Health Care / DTIL / earnings

ARTV (39) PALI (43) PLX (28) CGEN (78) ⌘ Pro Terminal →

Precision BioSciences Inc. (DTIL) Next Earnings Date & Expected ±12.5% Move

$7.06 -5.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.98

Precision BioSciences Inc. (DTIL) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $205.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DTIL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DTIL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Precision BioSciences Inc. (NASDAQ: DTIL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $7.06 (-5.11% 1D, market cap $205.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DTIL ranks #954 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DTIL compare to ARTV and PALI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DTIL carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M) and PALI (Palisade Bio Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DTIL?

▼

Per DTIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001357874), Precision BioSciences Inc. generated $34.3M in revenue (-50.1% YoY), -$45.7M in net income, and -$65.8M in free cash flow against $154.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.98 (-1.11%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DTIL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY DTIL SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (33% of score)

FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 55.8 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.72-14.1% Next Q

Q2 (-2Q)

Grade E$5.77+15.1% Next Q

Q3 (-1Q)

Grade E$6.64+6.3% Next Q

Current

Grade E$7.06-10.9% Hist 90D α

Trajectory: E (16) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DTIL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DTIL currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.90) and Max Pain ($7.41) forces dealer call-delta covering toward $10.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DTIL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DTIL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.88 Expected Swing

MODEL EARNINGS SETUP GAUGE

DTIL Quantitative Pre-Earnings Setup: 24/100

Trailing EPS: $4.25 • YoY Revenue Growth: -50.1%

Model Bullish Setup (24/100)Model Risk Weight (76/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$34.3M	-$45.7M	-$65.8M	52%
FY 2024	2024-12-31	$68.7M	$7.2M	-$58.4M	52%
FY 2023	2023-12-31	$48.7M	-$61.3M	-$84.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DTIL)

✓Walkthrough of DTIL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DTIL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.26%▼ DESCENDING CHANNEL

2026-10-30O $7.31H $7.42L $6.97C $7.06VOL 108.9K

RES: $8.90SUP: $5.55SMA50: $6.90SMA200: $6.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DTIL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DTIL Butterfly Map → + Track DTIL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -50.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DTIL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DTIL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DTIL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DTIL)

Health Care Rank #954 of 1016 ⚔️ ARTV vs DTIL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DTIL vs. ARTV, PALI, PLX, CGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Precision BioSciences Inc. (DTIL) ranks #954 by composite RQD confidence (24/100, grade E) and #574 by equity capitalization ($205.4M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with DTIL at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DTIL ACTIVE Precision BioSciences Inc.	E	24/100	—	—	-35.0%	-5.11%	$205.4M	Benchmark Subject
ARTV Artiva Biotherapeutics Inc.	D-	39/100	—	—	-35.0%	-0.95%	$206.8M	/artv-vs-dtil →
PALI Palisade Bio Inc.	D-	43/100	—	—	-35.0%	-2.52%	$207.4M	/pali-vs-dtil →
PLX Protalix BioTherapeutics Inc.	E	28/100	—	48.8%	-13.0%	-0.77%	$210.3M	/plx-vs-dtil →
CGEN Compugen Ltd.	B+	78/100	5.5x	87.3%	85.0%	-2.94%	$193.0M	/cgen-vs-dtil →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001357874

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precision BioSciences Inc. (DTIL) reported GAAP revenue of $34.3M (-50.1% vs. FY2024 revenue of $68.7M , and -29.7% cumulative change since FY2023) , GAAP net income of -$45.7M, operating cash flow of -$65.8M, and free cash flow of -$65.8M (-12.7% YoY). On the balance sheet, DTIL closed FY2025 with $154.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$34.3M	-$45.7M	-$65.8M	-$65.8M	$154.4M	—
FY2024 (FY)	2024-12-31	$68.7M	$7.2M	-$58.4M	-$58.4M	$136.4M	—
FY2023 (FY)	2023-12-31	$48.7M	-$61.3M	-$84.1M	-$84.1M	—	—

3. DTIL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DTIL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DTIL compare to ARTV and PALI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DTIL?

Where is DTIL trading relative to its 50-day, 200-day, and 52-week technical levels?

DTIL last traded at $7.06 (-5.11% on volume of 108,937 shares), positioning the stock +2.32% above its 50-day simple moving average ($6.90) and +7.95% above its 200-day simple moving average ($6.54). Across its 52-week range of $3.53 to $9.62, DTIL sits at the 58.0% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($6.18 to $7.94).

DTIL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is DTIL's next earnings date?

Based on SEC filing cadence, Precision BioSciences Inc. (DTIL)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is DTIL stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for DTIL, spanning a range between $6.18 and $7.94.

Direct Sub-Reports: DTIL RQD Cockpit DTIL 12M Forecast DTIL Earnings & Move DTIL Dividends & DRIP DTIL Insiders & 13F DTIL Whale Options DTIL Profit Sankey DTIL News & Why

ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DTIL — Precision BioSciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating for DTIL is 24 out of 100, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars break down as follows:

Fundamental Cash Engine: 3 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating returns on invested capital or free cash flow that would support valuation on cash-earnings grounds.
Whale 13F Flow: 8 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is weak, indicating limited evidence of institutional conviction in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score signals little insider or congressional buying conviction.
Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The score indicates the stock's macro exposure is not a meaningful offset to its company-specific weaknesses.
Forensic Balance Sheet: 2 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 1/9, and Debt/Equity is 0.5. The very low score signals elevated financial-distress and forensic risk.

Taken together, the investor implication is that the rating's downside drivers (negative ROIC, zero FCF yield, weak forensic scores, minimal insider conviction) dominate. Any upside thesis would need to rest on factors outside the cash-engine and balance-sheet pillars, and the source data does not establish such a thesis. The rating is educational context, not a recommendation.

Business

Precision BioSciences Inc. (DTIL) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances) (per the profile). The source data does not describe the company's products, customers, or revenue model. Revenue is reported in the SEC financials, but the source data does not break it down by source or customer. Not available in source data for further business detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$34.3M	$-52.1M	$-45.7M	N/A	$-65.8M	$110.8M	N/A
FY 2024	$68.7M	$-26.2M	$7.2M	N/A	$-58.4M	$85.9M	N/A
FY 2023	$48.7M	$-43.7M	$-61.3M	N/A	$-84.1M	N/A	N/A

Per the SEC financials, revenue fell from $68.7M in FY 2024 to $34.3M in FY 2025, and operating income was negative in every reported period. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, Altman Z is 0.2 and Piotroski F is 1/9, both indicating weak forensic health. Per the Roarable RQD rating, Debt/Equity is 0.5; the source data does not provide a debt figure for any period.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most significant dated item is a headline stating Precision BioSciences will report third-quarter 2026 financial results on November 3, 2026. Another item announces a late-breaking oral presentation for PBGENE-HBV at AASLD The Liver Meeting 2026. Other items are generic market-data posts. One item reports the stock slipping 6.48% to $5.77 as shares retreat toward $5.48 support; this conflicts with the current price of $7.06 in the market data and should be treated as unverified. All news items are tagged YELLOW with MARKET WIRE impact. The butterfly supply-chain graph reports supply_chain as NONE with no butterfly links and no proprietary signals, so no supply-chain or proprietary signal catalysts are recorded.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, there are no upstream or downstream dependencies, no butterfly links, and no proprietary signals. Sector correlations and 2nd-order bottlenecks cannot be mapped from the source data. An investor should note the Q3 2026 results date as the next known event to watch for changes in the reported financial trend.

Open Questions

What is the company's debt level and maturity profile, given the source data lists debt as N/A for every period?
What are the valuation metrics (P/E, EV/EBITDA, EPS), which the source data does not provide given negative earnings?
What drove the swing from FY 2024 net income of $7.2M to losses in FY 2025 and FY 2023?
What is the revenue and product mix behind the decline from $68.7M to $34.3M?
Which price is current, given one news item cites $5.77 while market data shows $7.06?

DTIL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Precision BioSciences Inc. (DTIL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DTIL Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 14h ago

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Yahoo Finance report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 17h ago

Precision BioSciences, Inc. Estimates – NASDAQ:DTIL

TradingView report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 20h ago

Precision BioSciences, Inc. (DTIL) Seasonal returns chart

Yahoo Finance UK report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 23h ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

Business Wire report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Precision BioSciences (DTIL) Slips 6.48% to $5.77 as Shares Retreat Toward $5.48 Support - Point of Control

https://www.siam.in/ report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Precision BioSciences, Inc. (DTIL) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Precision BioSciences stock has a November 2, 2026 earnings date

ad-hoc-news.de report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Precision BioSciences (DTIL) Slides 6.48% to $5.77 as Shares Test Lower Support - Backspread Trade

https://www.dars.gov.et/ report covering Precision BioSciences Inc. (DTIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DTIL Bull vs. Bear Conversation Board — What's Your Call at $7.06?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DTIL 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.21 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DTIL (E • RQD 24/100) a Buy at $7.06?

Welcome to the DTIL (Precision BioSciences Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.86 (-17.0%)

Spot @ $7.06

Pump the brakes on DTIL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DTIL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Precision BioSciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.47 (+20.0%)

Spot @ $7.06

DTIL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DTIL, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.06 (52-wk range $3.53 - $9.62), any beat on forward guidance forces shorts and underweight funds to chase.